PWM
VRTX icon

Perigon Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Perigon Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39M Buy
8,834
+2,380
+37% +$1.05M 0.07% 253
2026
Q1 		$2.88M Buy
6,454
+410
+7% +$191K 0.05% 303
2025
Q4 		$2.74M Sell
6,044
-64
-1% -$27.6K 0.05% 304
2025
Q3 		$2.39M Buy
6,108
+104
+2% +$43.5K 0.05% 311
2025
Q2 		$2.67M Buy
6,004
+724
+14% +$334K 0.06% 281
2025
Q1 		$2.56M Buy
5,280
+337
+7% +$157K 0.07% 270
2024
Q4 		$2.06M Buy
4,943
+94
+2% +$43.6K 0.05% 304
2024
Q3 		$2.26M Buy
+4,849
New +$2.33M 0.06% 270
2024
Q1 		– Sell
-1,432
Closed -$583K – 906
2023
Q4 		$583K Buy
1,432
+8
+0.6% +$2.96K 0.02% 459
2023
Q3 		$495K Sell
1,424
-124
-8% -$43.4K 0.02% 447
2023
Q2 		$545K Buy
1,548
+216
+16% +$72.8K 0.02% 438
2023
Q1 		$420K Sell
1,332
-407
-23% -$122K 0.02% 434
2022
Q4 		$502K Buy
1,739
+147
+9% +$44.8K 0.03% 387
2022
Q3 		$461K Sell
1,592
-1,038
-39% -$299K 0.04% 346
2022
Q2 		$741K Sell
2,630
-1,011
-28% -$271K 0.06% 254
2022
Q1 		$950K Buy
3,641
+526
+17% +$125K 0.07% 240
2021
Q4 		$684K Buy
3,115
+444
+17% +$86.3K 0.05% 279
2021
Q3 		$484K Sell
2,671
-469
-15% -$91.6K 0.04% 311
2021
Q2 		$633K Buy
3,140
+996
+46% +$208K 0.06% 261
2021
Q1 		$461K Buy
2,144
+1,403
+189% +$308K 0.05% 308
2020
Q4 		$175K Buy
+741
New +$170K 0.02% 418
2018
Q2 		– Sell
-65
Closed -$11K – 585
2018
Q1 		$11K Hold
65
– – ﹤0.01% 507
2017
Q4 		$10K Hold
65
– – ﹤0.01% 493
2017
Q3 		$10K Buy
+65
New +$9.78K ﹤0.01% 513

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Perigon Wealth Management's VRTX Position: Q2 2026 in Review

Perigon Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 37% in Q2 2026, buying an estimated $1.05M and bringing the position to 8,834 shares worth $4.39M. The position accounts for 0.07% of the portfolio, ranked #253.

Perigon Wealth Management first reported a position in VRTX in Q3 2017 and has held it in 24 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Perigon Wealth Management held 8,834 shares of Vertex Pharmaceuticals worth $4.39M as of Q2 2026.
  • Perigon Wealth Management bought 2,380 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Vertex Pharmaceuticals made up 0.07% of Perigon Wealth Management's portfolio in Q2 2026, its #253 holding.
  • Perigon Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.